FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979427641> ?p ?o ?g. }

• W2979427641 endingPage "vi85" @default.
• W2979427641 startingPage "vi85" @default.
• W2979427641 abstract "Abstract Background Pembro is approved for microsatellite instability-high (MSI-H)/dMMR CRC that has progressed on fluoropyrimidine+oxaliplatin+irinotecan (Fp+Ox+Ir), based in part on data from the ongoing phase 2 KEYNOTE-164 study (NCT02460198). The outcomes of the Japan (Jpn) subgroup of patients (pts) with dMMR CRC are reported. Methods Pts with metastatic MSI-H/dMMR CRC with ≥2 lines of standard therapy (Fp+Ox+Ir ± anti-VEGF or anti-EGFR; cohort A) or ≥ 1 prior line of therapy (cohort B) received pembro 200 mg every 3 weeks for 2 years or until progression or unacceptable toxicity. Response was assessed every 9 weeks per RECIST v1.1. Primary end point was objective response rate (ORR); secondary end points were duration of response (DOR), disease control rate, progression-free survival (PFS), overall survival (OS), and safety. Data cutoff was February 10, 2017 (cohort A) and September 12, 2017 (cohort B). Results Of the 124 enrolled pts, the Jpn subgroup comprised 7/61 pts in cohort A (cohort AJpn) and 6/63 pts in cohort B (cohort BJpn). At data cutoff, median follow-up was 13.2 months/13.2 months for cohorts A/AJpn and 12.6 months/13.6 months for cohorts B/BJpn. ORRs were 28% (95% CI, 20-44; 17 partial responses [PRs]) and 29% (95% CI, 4-71; 2 PRs) for cohorts A and AJpn, respectively, and 32% (95% CI, 21-45; 2 complete responses and 18 PRs) and 67% (95% CI, 22-96; 4 PRs) for cohorts B and BJpn, respectively. Median DOR was not reached for any group. 12-month PFS rates were 34%/29% for cohorts A/AJpn and 41%/67% for cohorts B/BJpn. 12-month OS rates were 72%/57% and 76%/100%, respectively. Treatment-related adverse events tended to occur more frequently in the Jpn subgroups than in the overall cohorts (57%/71% in cohorts A/AJpn and 64%/83% in cohorts B/BJpn), but the difference was not statistically significant. There were no treatment-related deaths. Conclusions Pembro provided safe and durable antitumor activity, even in the Jpn subgroup, with no new safety signals." @default.
• W2979427641 created "2019-10-18" @default.
• W2979427641 creator A5015799240 @default.
• W2979427641 creator A5031973387 @default.
• W2979427641 creator A5034503817 @default.
• W2979427641 creator A5040778303 @default.
• W2979427641 creator A5050468802 @default.
• W2979427641 creator A5050789569 @default.
• W2979427641 creator A5060366426 @default.
• W2979427641 creator A5062748030 @default.
• W2979427641 creator A5065329757 @default.
• W2979427641 creator A5068793485 @default.
• W2979427641 creator A5070275554 @default.
• W2979427641 creator A5077255843 @default.
• W2979427641 date "2019-10-01" @default.
• W2979427641 modified "2023-10-16" @default.
• W2979427641 title "Pembrolizumab (pembro) in Mismatch Repair-Deficient (dMMR) Advanced Colorectal Cancer (CRC): KEYNOTE-164 Japan Subgroup" @default.
• W2979427641 doi "https://doi.org/10.1093/annonc/mdz339.012" @default.
• W2979427641 hasPublicationYear "2019" @default.
• W2979427641 type Work @default.
• W2979427641 sameAs 2979427641 @default.
• W2979427641 citedByCount "1" @default.
• W2979427641 countsByYear W29794276412022 @default.
• W2979427641 crossrefType "journal-article" @default.
• W2979427641 hasAuthorship W2979427641A5015799240 @default.
• W2979427641 hasAuthorship W2979427641A5031973387 @default.
• W2979427641 hasAuthorship W2979427641A5034503817 @default.
• W2979427641 hasAuthorship W2979427641A5040778303 @default.
• W2979427641 hasAuthorship W2979427641A5050468802 @default.
• W2979427641 hasAuthorship W2979427641A5050789569 @default.
• W2979427641 hasAuthorship W2979427641A5060366426 @default.
• W2979427641 hasAuthorship W2979427641A5062748030 @default.
• W2979427641 hasAuthorship W2979427641A5065329757 @default.
• W2979427641 hasAuthorship W2979427641A5068793485 @default.
• W2979427641 hasAuthorship W2979427641A5070275554 @default.
• W2979427641 hasAuthorship W2979427641A5077255843 @default.
• W2979427641 hasBestOaLocation W29794276411 @default.
• W2979427641 hasConcept C121608353 @default.
• W2979427641 hasConcept C126322002 @default.
• W2979427641 hasConcept C143998085 @default.
• W2979427641 hasConcept C2777701055 @default.
• W2979427641 hasConcept C2780057760 @default.
• W2979427641 hasConcept C526805850 @default.
• W2979427641 hasConcept C71924100 @default.
• W2979427641 hasConceptScore W2979427641C121608353 @default.
• W2979427641 hasConceptScore W2979427641C126322002 @default.
• W2979427641 hasConceptScore W2979427641C143998085 @default.
• W2979427641 hasConceptScore W2979427641C2777701055 @default.
• W2979427641 hasConceptScore W2979427641C2780057760 @default.
• W2979427641 hasConceptScore W2979427641C526805850 @default.
• W2979427641 hasConceptScore W2979427641C71924100 @default.
• W2979427641 hasLocation W29794276411 @default.
• W2979427641 hasOpenAccess W2979427641 @default.
• W2979427641 hasPrimaryLocation W29794276411 @default.
• W2979427641 hasRelatedWork W2062691140 @default.
• W2979427641 hasRelatedWork W2517747645 @default.
• W2979427641 hasRelatedWork W2521234799 @default.
• W2979427641 hasRelatedWork W2585407512 @default.
• W2979427641 hasRelatedWork W2891524425 @default.
• W2979427641 hasRelatedWork W2945780494 @default.
• W2979427641 hasRelatedWork W3037068108 @default.
• W2979427641 hasRelatedWork W3041652591 @default.
• W2979427641 hasRelatedWork W4200023723 @default.
• W2979427641 hasRelatedWork W4281564228 @default.
• W2979427641 hasVolume "30" @default.
• W2979427641 isParatext "false" @default.
• W2979427641 isRetracted "false" @default.
• W2979427641 magId "2979427641" @default.
• W2979427641 workType "article" @default.